Health Care [ 7/12 ] | Biotechnology [ 33/76 ]
NASDAQ | Common Stock
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases.
Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in theU. S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria.
It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome.
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020.
Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -0.91 Increased by +19.47% | -0.86 Decreased by -5.81% |
| May 6, 24 | -1.76 Decreased by -38.58% | -0.99 Decreased by -77.78% |
| Mar 12, 24 | -1.18 Decreased by -14.56% | -1.27 Increased by +7.09% |
| Nov 7, 23 | -1.17 Decreased by -7.34% | -0.14 Decreased by -735.71% |
| Aug 3, 23 | -1.13 Decreased by -7.62% | -1.16 Increased by +2.59% |
| May 4, 23 | -1.27 Decreased by -5.83% | -1.17 Decreased by -8.55% |
| Feb 23, 23 | -1.03 Decreased by -22.62% | -1.07 Increased by +3.74% |
| Oct 27, 22 | -1.09 Decreased by -84.75% | -0.86 Decreased by -26.74% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 41.37 M Decreased by -27.41% | -136.06 M Decreased by -57.60% | Decreased by -328.86% Decreased by -117.10% |
| Dec 31, 23 | 45.06 M Decreased by -19.35% | -90.17 M Decreased by -36.99% | Decreased by -200.12% Decreased by -69.86% |
| Sep 30, 23 | 37.09 M Decreased by -30.66% | 150.74 M Increased by +316.40% | Increased by +406.35% Increased by +412.08% |
| Jun 30, 23 | 59.70 M Increased by +10.21% | -85.63 M Decreased by -27.74% | Decreased by -143.44% Decreased by -15.91% |
| Mar 31, 23 | 56.99 M Increased by +17.54% | -86.33 M Decreased by -13.64% | Decreased by -151.48% Increased by +3.32% |
| Dec 31, 22 | 55.87 M Decreased by -2.41% | -65.82 M Decreased by -27.63% | Decreased by -117.82% Decreased by -30.79% |
| Sep 30, 22 | 53.50 M Decreased by -21.58% | -69.66 M Decreased by -95.45% | Decreased by -130.21% Decreased by -149.23% |
| Jun 30, 22 | 54.17 M Decreased by -0.82% | -67.03 M Decreased by -71.82% | Decreased by -123.75% Decreased by -73.25% |